0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Oncology Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: April 2024
|
Report Code: QYRE-Auto-4R430
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Oncology Drugs Market Size Status and Forecast 2021 2027
BUY CHAPTERS

Oncology Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-4R430
Report
April 2024
Pages:153
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Oncology Drugs - Market Size

The global market for Oncology Drugs was estimated to be worth US$ 197440 million in 2023 and is forecast to a readjusted size of US$ 395270 million by 2030 with a CAGR of 10.3% during the forecast period 2024-2030

Oncology Drugs - Market

Oncology Drugs - Market

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
The industry's leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues. By region, North America had the highest share of income, at 43%.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oncology Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oncology Drugs by region & country, by Type, and by Application.
The Oncology Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Drugs.
Market Segmentation

Scope of Oncology Drugs - Market Report

Report Metric Details
Report Name Oncology Drugs - Market
Forecasted market size in 2030 US$ 395270 million
CAGR 10.3%
Forecasted years 2024 - 2030
Segment by Type:
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Others
Segment by Application
  • Blood Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Respiratory or Lung Cancer
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Oncology Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Oncology Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Oncology Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Oncology Drugs - Market size in 2030?

Ans: The Oncology Drugs - Market size in 2030 will be US$ 395270 million.

What is the Roche, Celgene, Novartis share in Oncology Drugs - Market?

Ans: The industry's leading producers include Roche, Celgene and Novartis, which together account for 35% of their revenues.

What is the Oncology Drugs - Market share by region?

Ans: By region, North America had the highest share of income, at 43%.

Who are the main players in the Oncology Drugs - Market report?

Ans: The main players in the Oncology Drugs - Market are Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences

What are the Application segmentation covered in the Oncology Drugs - Market report?

Ans: The Applications covered in the Oncology Drugs - Market report are Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory or Lung Cancer, Others

What are the Type segmentation covered in the Oncology Drugs - Market report?

Ans: The Types covered in the Oncology Drugs - Market report are Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Others

1 Market Overview
1.1 Oncology Drugs Product Introduction
1.2 Global Oncology Drugs Market Size Forecast
1.3 Oncology Drugs Market Trends & Drivers
1.3.1 Oncology Drugs Industry Trends
1.3.2 Oncology Drugs Market Drivers & Opportunity
1.3.3 Oncology Drugs Market Challenges
1.3.4 Oncology Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Oncology Drugs Players Revenue Ranking (2023)
2.2 Global Oncology Drugs Revenue by Company (2019-2024)
2.3 Key Companies Oncology Drugs Manufacturing Base Distribution and Headquarters
2.4 Key Companies Oncology Drugs Product Offered
2.5 Key Companies Time to Begin Mass Production of Oncology Drugs
2.6 Oncology Drugs Market Competitive Analysis
2.6.1 Oncology Drugs Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Oncology Drugs Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Drugs as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Chemotherapy
3.1.2 Targeted Therapy
3.1.3 Immunotherapy (Biologic Therapy)
3.1.4 Hormonal Therapy
3.1.5 Others
3.2 Global Oncology Drugs Sales Value by Type
3.2.1 Global Oncology Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Oncology Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Oncology Drugs Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Blood Cancer
4.1.2 Breast Cancer
4.1.3 Gastrointestinal Cancer
4.1.4 Prostate Cancer
4.1.5 Respiratory or Lung Cancer
4.1.6 Others
4.2 Global Oncology Drugs Sales Value by Application
4.2.1 Global Oncology Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Oncology Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Oncology Drugs Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Oncology Drugs Sales Value by Region
5.1.1 Global Oncology Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Oncology Drugs Sales Value by Region (2019-2024)
5.1.3 Global Oncology Drugs Sales Value by Region (2025-2030)
5.1.4 Global Oncology Drugs Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Oncology Drugs Sales Value, 2019-2030
5.2.2 North America Oncology Drugs Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Oncology Drugs Sales Value, 2019-2030
5.3.2 Europe Oncology Drugs Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Oncology Drugs Sales Value, 2019-2030
5.4.2 Asia Pacific Oncology Drugs Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Oncology Drugs Sales Value, 2019-2030
5.5.2 South America Oncology Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Oncology Drugs Sales Value, 2019-2030
5.6.2 Middle East & Africa Oncology Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Oncology Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Oncology Drugs Sales Value
6.3 United States
6.3.1 United States Oncology Drugs Sales Value, 2019-2030
6.3.2 United States Oncology Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Oncology Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Oncology Drugs Sales Value, 2019-2030
6.4.2 Europe Oncology Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Oncology Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Oncology Drugs Sales Value, 2019-2030
6.5.2 China Oncology Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Oncology Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Oncology Drugs Sales Value, 2019-2030
6.6.2 Japan Oncology Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Oncology Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Oncology Drugs Sales Value, 2019-2030
6.7.2 South Korea Oncology Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Oncology Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Oncology Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Oncology Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Oncology Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Oncology Drugs Sales Value, 2019-2030
6.9.2 India Oncology Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Oncology Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Roche
7.1.1 Roche Profile
7.1.2 Roche Main Business
7.1.3 Roche Oncology Drugs Products, Services and Solutions
7.1.4 Roche Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.1.5 Roche Recent Developments
7.2 Celgene
7.2.1 Celgene Profile
7.2.2 Celgene Main Business
7.2.3 Celgene Oncology Drugs Products, Services and Solutions
7.2.4 Celgene Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.2.5 Celgene Recent Developments
7.3 Novartis
7.3.1 Novartis Profile
7.3.2 Novartis Main Business
7.3.3 Novartis Oncology Drugs Products, Services and Solutions
7.3.4 Novartis Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.3.5 Bristol-Myers Squibb Recent Developments
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Profile
7.4.2 Bristol-Myers Squibb Main Business
7.4.3 Bristol-Myers Squibb Oncology Drugs Products, Services and Solutions
7.4.4 Bristol-Myers Squibb Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.4.5 Bristol-Myers Squibb Recent Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Profile
7.5.2 Johnson & Johnson Main Business
7.5.3 Johnson & Johnson Oncology Drugs Products, Services and Solutions
7.5.4 Johnson & Johnson Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.5.5 Johnson & Johnson Recent Developments
7.6 Merck & Co.
7.6.1 Merck & Co. Profile
7.6.2 Merck & Co. Main Business
7.6.3 Merck & Co. Oncology Drugs Products, Services and Solutions
7.6.4 Merck & Co. Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.6.5 Merck & Co. Recent Developments
7.7 AstraZeneca
7.7.1 AstraZeneca Profile
7.7.2 AstraZeneca Main Business
7.7.3 AstraZeneca Oncology Drugs Products, Services and Solutions
7.7.4 AstraZeneca Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.7.5 AstraZeneca Recent Developments
7.8 Pfizer
7.8.1 Pfizer Profile
7.8.2 Pfizer Main Business
7.8.3 Pfizer Oncology Drugs Products, Services and Solutions
7.8.4 Pfizer Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.8.5 Pfizer Recent Developments
7.9 Amgen
7.9.1 Amgen Profile
7.9.2 Amgen Main Business
7.9.3 Amgen Oncology Drugs Products, Services and Solutions
7.9.4 Amgen Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.9.5 Amgen Recent Developments
7.10 Eli Lilly
7.10.1 Eli Lilly Profile
7.10.2 Eli Lilly Main Business
7.10.3 Eli Lilly Oncology Drugs Products, Services and Solutions
7.10.4 Eli Lilly Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.10.5 Eli Lilly Recent Developments
7.11 AbbVie
7.11.1 AbbVie Profile
7.11.2 AbbVie Main Business
7.11.3 AbbVie Oncology Drugs Products, Services and Solutions
7.11.4 AbbVie Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.11.5 AbbVie Recent Developments
7.12 Takeda
7.12.1 Takeda Profile
7.12.2 Takeda Main Business
7.12.3 Takeda Oncology Drugs Products, Services and Solutions
7.12.4 Takeda Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.12.5 Takeda Recent Developments
7.13 Astellas
7.13.1 Astellas Profile
7.13.2 Astellas Main Business
7.13.3 Astellas Oncology Drugs Products, Services and Solutions
7.13.4 Astellas Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.13.5 Astellas Recent Developments
7.14 Ipsen
7.14.1 Ipsen Profile
7.14.2 Ipsen Main Business
7.14.3 Ipsen Oncology Drugs Products, Services and Solutions
7.14.4 Ipsen Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.14.5 Ipsen Recent Developments
7.15 Sanofi
7.15.1 Sanofi Profile
7.15.2 Sanofi Main Business
7.15.3 Sanofi Oncology Drugs Products, Services and Solutions
7.15.4 Sanofi Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.15.5 Sanofi Recent Developments
7.16 Bayer
7.16.1 Bayer Profile
7.16.2 Bayer Main Business
7.16.3 Bayer Oncology Drugs Products, Services and Solutions
7.16.4 Bayer Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.16.5 Bayer Recent Developments
7.17 Biogen Idec
7.17.1 Biogen Idec Profile
7.17.2 Biogen Idec Main Business
7.17.3 Biogen Idec Oncology Drugs Products, Services and Solutions
7.17.4 Biogen Idec Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.17.5 Biogen Idec Recent Developments
7.18 Teva
7.18.1 Teva Profile
7.18.2 Teva Main Business
7.18.3 Teva Oncology Drugs Products, Services and Solutions
7.18.4 Teva Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.18.5 Teva Recent Developments
7.19 Otsuka
7.19.1 Otsuka Profile
7.19.2 Otsuka Main Business
7.19.3 Otsuka Oncology Drugs Products, Services and Solutions
7.19.4 Otsuka Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.19.5 Otsuka Recent Developments
7.20 Eisai
7.20.1 Eisai Profile
7.20.2 Eisai Main Business
7.20.3 Eisai Oncology Drugs Products, Services and Solutions
7.20.4 Eisai Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.20.5 Eisai Recent Developments
7.21 Merck KGaA
7.21.1 Merck KGaA Profile
7.21.2 Merck KGaA Main Business
7.21.3 Merck KGaA Oncology Drugs Products, Services and Solutions
7.21.4 Merck KGaA Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.21.5 Merck KGaA Recent Developments
7.22 Gilead Sciences
7.22.1 Gilead Sciences Profile
7.22.2 Gilead Sciences Main Business
7.22.3 Gilead Sciences Oncology Drugs Products, Services and Solutions
7.22.4 Gilead Sciences Oncology Drugs Revenue (US$ Million) & (2019-2024)
7.22.5 Gilead Sciences Recent Developments
8 Industry Chain Analysis
8.1 Oncology Drugs Industrial Chain
8.2 Oncology Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Oncology Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Oncology Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
    Table 1. Oncology Drugs Market Trends
    Table 2. Oncology Drugs Market Drivers & Opportunity
    Table 3. Oncology Drugs Market Challenges
    Table 4. Oncology Drugs Market Restraints
    Table 5. Global Oncology Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Oncology Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Oncology Drugs Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Oncology Drugs Product Type
    Table 9. Key Companies Time to Begin Mass Production of Oncology Drugs
    Table 10. Global Oncology Drugs Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Drugs as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Oncology Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Oncology Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Oncology Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Oncology Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Oncology Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Oncology Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Oncology Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Oncology Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Oncology Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Oncology Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Oncology Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Oncology Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Oncology Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Oncology Drugs Sales Value by Region (2019-2024) & (%)
    Table 27. Global Oncology Drugs Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Oncology Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Oncology Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Oncology Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 31. Roche Basic Information List
    Table 32. Roche Description and Business Overview
    Table 33. Roche Oncology Drugs Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Oncology Drugs Business of Roche (2019-2024)
    Table 35. Roche Recent Developments
    Table 36. Celgene Basic Information List
    Table 37. Celgene Description and Business Overview
    Table 38. Celgene Oncology Drugs Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Oncology Drugs Business of Celgene (2019-2024)
    Table 40. Celgene Recent Developments
    Table 41. Novartis Basic Information List
    Table 42. Novartis Description and Business Overview
    Table 43. Novartis Oncology Drugs Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Oncology Drugs Business of Novartis (2019-2024)
    Table 45. Novartis Recent Developments
    Table 46. Bristol-Myers Squibb Basic Information List
    Table 47. Bristol-Myers Squibb Description and Business Overview
    Table 48. Bristol-Myers Squibb Oncology Drugs Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Oncology Drugs Business of Bristol-Myers Squibb (2019-2024)
    Table 50. Bristol-Myers Squibb Recent Developments
    Table 51. Johnson & Johnson Basic Information List
    Table 52. Johnson & Johnson Description and Business Overview
    Table 53. Johnson & Johnson Oncology Drugs Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Oncology Drugs Business of Johnson & Johnson (2019-2024)
    Table 55. Johnson & Johnson Recent Developments
    Table 56. Merck & Co. Basic Information List
    Table 57. Merck & Co. Description and Business Overview
    Table 58. Merck & Co. Oncology Drugs Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Oncology Drugs Business of Merck & Co. (2019-2024)
    Table 60. Merck & Co. Recent Developments
    Table 61. AstraZeneca Basic Information List
    Table 62. AstraZeneca Description and Business Overview
    Table 63. AstraZeneca Oncology Drugs Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Oncology Drugs Business of AstraZeneca (2019-2024)
    Table 65. AstraZeneca Recent Developments
    Table 66. Pfizer Basic Information List
    Table 67. Pfizer Description and Business Overview
    Table 68. Pfizer Oncology Drugs Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Oncology Drugs Business of Pfizer (2019-2024)
    Table 70. Pfizer Recent Developments
    Table 71. Amgen Basic Information List
    Table 72. Amgen Description and Business Overview
    Table 73. Amgen Oncology Drugs Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Oncology Drugs Business of Amgen (2019-2024)
    Table 75. Amgen Recent Developments
    Table 76. Eli Lilly Basic Information List
    Table 77. Eli Lilly Description and Business Overview
    Table 78. Eli Lilly Oncology Drugs Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Oncology Drugs Business of Eli Lilly (2019-2024)
    Table 80. Eli Lilly Recent Developments
    Table 81. AbbVie Basic Information List
    Table 82. AbbVie Description and Business Overview
    Table 83. AbbVie Oncology Drugs Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Oncology Drugs Business of AbbVie (2019-2024)
    Table 85. AbbVie Recent Developments
    Table 86. Takeda Basic Information List
    Table 87. Takeda Description and Business Overview
    Table 88. Takeda Oncology Drugs Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Oncology Drugs Business of Takeda (2019-2024)
    Table 90. Takeda Recent Developments
    Table 91. Astellas Basic Information List
    Table 92. Astellas Description and Business Overview
    Table 93. Astellas Oncology Drugs Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Oncology Drugs Business of Astellas (2019-2024)
    Table 95. Astellas Recent Developments
    Table 96. Ipsen Basic Information List
    Table 97. Ipsen Description and Business Overview
    Table 98. Ipsen Oncology Drugs Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Oncology Drugs Business of Ipsen (2019-2024)
    Table 100. Ipsen Recent Developments
    Table 101. Sanofi Basic Information List
    Table 102. Sanofi Description and Business Overview
    Table 103. Sanofi Oncology Drugs Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Oncology Drugs Business of Sanofi (2019-2024)
    Table 105. Sanofi Recent Developments
    Table 106. Bayer Basic Information List
    Table 107. Bayer Description and Business Overview
    Table 108. Bayer Oncology Drugs Products, Services and Solutions
    Table 109. Revenue (US$ Million) in Oncology Drugs Business of Bayer (2019-2024)
    Table 110. Bayer Recent Developments
    Table 111. Biogen Idec Basic Information List
    Table 112. Biogen Idec Description and Business Overview
    Table 113. Biogen Idec Oncology Drugs Products, Services and Solutions
    Table 114. Revenue (US$ Million) in Oncology Drugs Business of Biogen Idec (2019-2024)
    Table 115. Biogen Idec Recent Developments
    Table 116. Teva Basic Information List
    Table 117. Teva Description and Business Overview
    Table 118. Teva Oncology Drugs Products, Services and Solutions
    Table 119. Revenue (US$ Million) in Oncology Drugs Business of Teva (2019-2024)
    Table 120. Teva Recent Developments
    Table 121. Otsuka Basic Information List
    Table 122. Otsuka Description and Business Overview
    Table 123. Otsuka Oncology Drugs Products, Services and Solutions
    Table 124. Revenue (US$ Million) in Oncology Drugs Business of Otsuka (2019-2024)
    Table 125. Otsuka Recent Developments
    Table 126. Eisai Basic Information List
    Table 127. Eisai Description and Business Overview
    Table 128. Eisai Oncology Drugs Products, Services and Solutions
    Table 129. Revenue (US$ Million) in Oncology Drugs Business of Eisai (2019-2024)
    Table 130. Eisai Recent Developments
    Table 131. Merck KGaA Basic Information List
    Table 132. Merck KGaA Description and Business Overview
    Table 133. Merck KGaA Oncology Drugs Products, Services and Solutions
    Table 134. Revenue (US$ Million) in Oncology Drugs Business of Merck KGaA (2019-2024)
    Table 135. Merck KGaA Recent Developments
    Table 136. Gilead Sciences Basic Information List
    Table 137. Gilead Sciences Description and Business Overview
    Table 138. Gilead Sciences Oncology Drugs Products, Services and Solutions
    Table 139. Revenue (US$ Million) in Oncology Drugs Business of Gilead Sciences (2019-2024)
    Table 140. Gilead Sciences Recent Developments
    Table 141. Key Raw Materials Lists
    Table 142. Raw Materials Key Suppliers Lists
    Table 143. Oncology Drugs Downstream Customers
    Table 144. Oncology Drugs Distributors List
    Table 145. Research Programs/Design for This Report
    Table 146. Key Data Information from Secondary Sources
    Table 147. Key Data Information from Primary Sources
    Table 148. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Oncology Drugs Product Picture
    Figure 2. Global Oncology Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Oncology Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. Oncology Drugs Report Years Considered
    Figure 5. Global Oncology Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Oncology Drugs Revenue in 2023
    Figure 7. Oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Chemotherapy Picture
    Figure 9. Targeted Therapy Picture
    Figure 10. Immunotherapy (Biologic Therapy) Picture
    Figure 11. Hormonal Therapy Picture
    Figure 12. Others Picture
    Figure 13. Global Oncology Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Oncology Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Product Picture of Blood Cancer
    Figure 16. Product Picture of Breast Cancer
    Figure 17. Product Picture of Gastrointestinal Cancer
    Figure 18. Product Picture of Prostate Cancer
    Figure 19. Product Picture of Respiratory or Lung Cancer
    Figure 20. Product Picture of Others
    Figure 21. Global Oncology Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 22. Global Oncology Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 23. North America Oncology Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 24. North America Oncology Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 25. Europe Oncology Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 26. Europe Oncology Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 27. Asia Pacific Oncology Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 28. Asia Pacific Oncology Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 29. South America Oncology Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 30. South America Oncology Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 31. Middle East & Africa Oncology Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 32. Middle East & Africa Oncology Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 33. Key Countries/Regions Oncology Drugs Sales Value (%), (2019-2030)
    Figure 34. United States Oncology Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 35. United States Oncology Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 36. United States Oncology Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 37. Europe Oncology Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 38. Europe Oncology Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 39. Europe Oncology Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 40. China Oncology Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 41. China Oncology Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 42. China Oncology Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 43. Japan Oncology Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Japan Oncology Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 45. Japan Oncology Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 46. South Korea Oncology Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 47. South Korea Oncology Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 48. South Korea Oncology Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 49. Southeast Asia Oncology Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 50. Southeast Asia Oncology Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 51. Southeast Asia Oncology Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 52. India Oncology Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 53. India Oncology Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 54. India Oncology Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 55. Oncology Drugs Industrial Chain
    Figure 56. Oncology Drugs Manufacturing Cost Structure
    Figure 57. Channels of Distribution (Direct Sales, and Distribution)
    Figure 58. Bottom-up and Top-down Approaches for This Report
    Figure 59. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS